S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.14 (+0.18%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.68 (-15.21%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.14 (+0.18%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.68 (-15.21%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.14 (+0.18%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.68 (-15.21%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.14 (+0.18%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.68 (-15.21%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
NASDAQ:ONCY

Oncolytics Biotech (ONCY) Stock Price, News & Analysis

$1.04
+0.02 (+1.46%)
(As of 02:15 PM ET)
Today's Range
$1.01
$1.06
50-Day Range
$0.89
$1.25
52-Week Range
$0.88
$3.39
Volume
235,643 shs
Average Volume
399,941 shs
Market Capitalization
$78.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Oncolytics Biotech MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
380.8% Upside
$5.00 Price Target
Short Interest
Healthy
1.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.32) to ($0.31) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.65 out of 5 stars

Medical Sector

426th out of 939 stocks

Biotechnology Industry

9th out of 24 stocks

ONCY stock logo

About Oncolytics Biotech Stock (NASDAQ:ONCY)

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

ONCY Stock Price History

ONCY Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Oncolytics Biotech Inc
See More Headlines
Receive ONCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2023
Today
3/28/2024
Next Earnings (Estimated)
5/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ONCY
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+385.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-20,560,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.27 per share

Miscellaneous

Free Float
75,345,000
Market Cap
$77.68 million
Optionable
Not Optionable
Beta
1.94
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Matthew C. Coffey M.B.A.
    Ph.D., President, CEO & Director
  • Mr. Kirk J. Look C.A.
    CA, Chief Financial Officer
  • Dr. Thomas C. Heineman M.D.
    Ph.D., Chief Medical Officer
  • Ms. Allison Hagerman P.Eng.
    P.M.P., Vice President of Product Development
  • Ms. Amy Goodowitz Levin
    Vice President of Clinical Operations
  • Jon Patton
    Director of Investor Relations & Communication
  • Mr. John Mark Lievonen BBA
    C.M., FCA, LLD, MBA, Consultant

ONCY Stock Analysis - Frequently Asked Questions

Should I buy or sell Oncolytics Biotech stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ONCY shares.
View ONCY analyst ratings
or view top-rated stocks.

What is Oncolytics Biotech's stock price target for 2024?

2 Wall Street analysts have issued 12 month target prices for Oncolytics Biotech's stock. Their ONCY share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 380.8% from the stock's current price.
View analysts price targets for ONCY
or view top-rated stocks among Wall Street analysts.

How have ONCY shares performed in 2024?

Oncolytics Biotech's stock was trading at $1.35 at the beginning of the year. Since then, ONCY stock has decreased by 23.0% and is now trading at $1.04.
View the best growth stocks for 2024 here
.

When is Oncolytics Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our ONCY earnings forecast
.

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech Inc. (NASDAQ:ONCY) posted its quarterly earnings data on Friday, November, 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.03. During the same quarter last year, the business posted ($0.06) EPS.

What is Brad Thompson's approval rating as Oncolytics Biotech's CEO?

2 employees have rated Oncolytics Biotech Chief Executive Officer Brad Thompson on Glassdoor.com. Brad Thompson has an approval rating of 56% among the company's employees. This puts Brad Thompson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), KushCo (KSHB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

Who are Oncolytics Biotech's major shareholders?

Oncolytics Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include International Assets Investment Management LLC (0.36%), Citadel Advisors LLC (0.15%), Advisor Resource Council (0.13%) and Ausdal Financial Partners Inc. (0.04%).

How do I buy shares of Oncolytics Biotech?

Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ONCY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners